Ga direct naar de inhoud

Ga direct naar de navigatie

Uitgave van

Berichten met het trefwoord ‘keytruda’

FDA approves Merck immunotherapy/chemo combo for lung cancer

Merck & Co said on Wednesday that U.S. health regulators approved its Keytruda in combination with chemotherapy for previously untreated advanced lung cancer, solidifying the drugmaker’s lead position in the field of medicines that help the immune system fight cancer.

Bron: Reuters Meer lezen »

MSD’s Keytruda notches another FDA approval in Hodgkin lymphoma

MSD, otherwise known as Merck in North America, continues to score indication successes with Keytruda, this time in Hodgkin lymphoma. The particular indication is within patients who are refractory to treatment or who have relapsed after three or more previous attempts at treatment.

Bron: Meer lezen »

Lung cancer doctors eye Merck’s Keytruda over Bristol’s Opdivo

Recent clinical trial results are likely to lead doctors to treat more patients who have a common form of lung cancer with a Merck drug at the expense of a Bristol-Myers Squibb medication at least until more data emerges, oncologists and analysts say.

Bron: Reuters Meer lezen »

FDA grants breakthrough therapy status to Merck’s Keytruda

Merck, a global health care leader announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Keytruda (pembrolizumab), the company’s anti─PD─1 therapy.

Bron: Pharma Biz Meer lezen »

MSD’s Keytruda shows promise in multiple myeloma

MSD has announced that it has initiated two Phase III studies based in part on the strength of early data, which found Keytruda may be effective for people with multiple myeloma.

Bron: Meer lezen »

FDA Approves Pembrolizumab for Lung Cancer

The programmed death (PD-1) inhibitor pembrolizumab (Keytruda, Merck & Co) has been granted approval by the US Food and Drug Administration (FDA) for use in lung cancer, becoming the second immunotherapy available for this tumor type.

Bron: RxList : The Internet Drug Index Meer lezen »